Epigenetics is one of the fastest moving fields in drug discovery, with almost every large pharmaceutical company, and a substantial number of biotechnology companies, targeting epigenetic processes to treat diseases ranging from cancer to Huntington's disease and from inflammation to sickle cell anaemia. This book aims to provide an overview of the key topics adopted in current epigenetic drug discovery programmes with a focus on major developments and new technologies. Importantly, the book incorporates case studies and outlines the key challenges and techniques employed to overcome them. The book is an ideal resource for researchers in both industry and academia with an interest in epigenetic and genetic factors involved in drug discovery, target ID and validation. The book is also an excellent introduction for postgraduates interested in the interface between epigenetics and pharmaceuticals.